Clinical complications in a series of patients with anticardiolipin antibodies

Authors

  • A. Pujol
  • E. Alegría
  • J. González
  • Ch. Ngare
  • J. Pérez
  • J.A. Páramo

Keywords:

Síndrome antifosfolípido. Anticuerpos anticardiolipina. Trombosis venosa. Trombosis arterial. Anticoagulante lúpico.

Abstract

An analysis was made of clinical complications, determined with objective methods, in 68 patients at the University Clinic of Navarra with the clinical suspicion of antiphospholipid syndrome (APS) and presence of anticardiolipin antibodies (ACA). Patients with IgG higher than 23 GPL were considered for the study. The most prevalent pathology was thrombosis: venous thrombosis (42.6%) and arterial thrombosis (22%). Other complications were abortions (23.8% of the 42 women) and thrombocytopenia (12.1%). With respect to the localisation of venous thrombosis, predominance corresponded to lower extremities (51.7%), followed by superficial thrombophlebitis (27.5%) and pulmonary thromboembolism (20.6%). Among the arterial complications, the most frequent were cerebrovascular disease (86.6 %) and coronary disease (13.4%). There was no correlation between the presence of high values of ACA and the prevalence or severity of clinical manifestations. In the series of patients with ACA IgG>23 GPL, we appreciated a high percentage of venous and arterial thrombosis detected with objective methods. The presence of ACA constitutes a prothrombotic risk factor.

Downloads

Download data is not yet available.

Published

2008-12-26

How to Cite

1.
Pujol A, Alegría E, González J, Ngare C, Pérez J, Páramo J. Clinical complications in a series of patients with anticardiolipin antibodies. An Sist Sanit Navar [Internet]. 2008 Dec. 26 [cited 2026 Feb. 1];26(3):365-72. Available from: https://recyt.fecyt.es/index.php/ASSN/article/view/5076

Issue

Section

Research articles

Most read articles by the same author(s)

Similar Articles

<< < 3 4 5 6 7 8 9 10 11 12 > >> 

You may also start an advanced similarity search for this article.